BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Sold by TD Asset Management Inc

Key Points

• TD Asset Management Inc significantly reduced its stake in BioNTech SE by 74% in the first quarter, selling over 32,000 shares and leaving them with a total of 11,452 shares valued at approximately $1.02 million.
• Despite the sell-off by TD Asset Management, several other institutional investors increased their holdings in BioNTech, with increases ranging from 7.1% to 34.2% among various firms.
• BioNTech reported a quarterly revenue of $306.46 million, exceeding analyst expectations, but it reported a loss of ($1.60) EPS, falling short of the anticipated ($1.41), indicating ongoing volatility in its earnings performance.

TD Asset Management Inc lessened its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 74.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,452 shares of the company's stock after selling 32,530 shares during the period. TD Asset Management Inc's holdings in BioNTech were worth $1,020,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Probity Advisors Inc. grew its holdings in shares of BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after purchasing an additional 154 shares during the last quarter. SBI Securities Co. Ltd. grew its stake in BioNTech by 7.1% during the 1st quarter. SBI Securities Co. Ltd. now owns 3,673 shares of the company's stock worth $334,000 after buying an additional 244 shares during the last quarter. GF Fund Management CO. LTD. increased its position in BioNTech by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock worth $229,000 after buying an additional 453 shares during the period. Vontobel Holding Ltd. increased its position in BioNTech by 2.3% during the first quarter. Vontobel Holding Ltd. now owns 21,882 shares of the company's stock worth $1,993,000 after buying an additional 497 shares during the period. Finally, Kestra Private Wealth Services LLC lifted its stake in BioNTech by 34.2% in the first quarter. Kestra Private Wealth Services LLC now owns 2,659 shares of the company's stock valued at $242,000 after buying an additional 678 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and set a $138.00 target price on shares of BioNTech in a research report on Wednesday, June 25th. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Bank of America lifted their price objective on shares of BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research note on Tuesday. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the stock an "overweight" rating in a research note on Tuesday. Finally, Citigroup reissued a "buy" rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $135.91.

BioNTech Price Performance

BNTX stock traded up $0.74 on Friday, reaching $112.09. 241,226 shares of the company's stock were exchanged, compared to its average volume of 948,312. The stock has a fifty day moving average of $109.08 and a 200-day moving average of $106.23. The firm has a market cap of $26.95 billion, a PE ratio of -70.11 and a beta of 1.23. The company has a quick ratio of 10.02, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $79.14 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. During the same quarter in the prior year, the business earned ($3.36) EPS. The business's revenue for the quarter was up 102.6% compared to the same quarter last year. As a group, equities analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.